The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
ATP and cancer immunosurveillance
Open accessAbstract
While intracellular adenosine triphosphate (ATP) occupies a key position in the bioenergetic metabolism of all the cellular compartments that form the tumor microenvironment (TME), extracellular ATP operates as a potent signal transducer. The net effects of purinergic signaling on the biology of the TME depend not only on the specific receptors and cell types involved, but also on the activation status of cis‐ and trans‐regulatory circuitries. As an additional layer of complexity, extracellular ATP is rapidly catabolized by ectonucleotidases, culminating in the accumulation of metabolites that mediate distinct biological effects. Here, we discuss the molecular and cellular mechanisms through which ATP and its degradation products influence cancer immunosurveillance, with a focus on therapeutically targetable circuitries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Self-citationLDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Brand, A., Singer, K., Koehl, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.011 · Cited by 2,039
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · cited 2×
“…as mice lacking a core component of the inflammasome ( Nlrp3 (cid:1) / (cid:1) mice), the main IL1B receptor ( Il1r1 (cid:1) / (cid:1) mice) or treated with a purinergic receptor antagonist (suramin) or an IL1B-blocking antibody (Ghiringhelli et al , 2009; Aymeric et al , 2010; Ma et al , 2013).”
Self-citationNucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045 · cited 1×
“However, CD38-specific agents (including the FDA-approved monoclonal antibody daratumumab) are currently used with the aim of eradicating CD38-expressing myeloma cells (Facon et al , 2019), and ENPP1 blockers are still in preclinical development (Carozza et al , 2020).”
Metabolism of immune cells in cancer
Leone, R. D., & Powell, J. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0273-y · Cited by 877 · cited 1×
“On one hand, intracellular ATP is crucial for each cellular TME component to survive and mediate its functions (including proliferation, for malignant and non-terminally differentiated immune cells) (Leone & Powell, 2020; Bergers & Fendt, 2021).”
NINJ1 mediates plasma membrane rupture during lytic cell death
Kayagaki, N., Kornfeld, O. S., Lee, B. L., Stowe, I. B., O’Rourke, K., Li, Q., Sandoval, W., Yan, D., Kang, J., Xu, M., et al. (2021) · Nature · doi:10.1038/s41586-021-03218-7 · Cited by 857 · cited 1×
“However, while PMP itself has now been shown to be an active (rather than an osmosis-driven) process even in the context of post-apoptotic, secondary necrosis (Kayagaki et al , 2021), the consequent spillage of cytosolic content into the extracellular milieu remains a largely unregulated phenomenon.”
Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase
Pellegatti, P., Raffaghello, L., Bianchi, G., Piccardi, F., Pistoia, V., & Di Virgilio, F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002599 · Cited by 668
The hallmarks of successful anticancer immunotherapy
Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575
Self-citationMolecular mechanisms of ATP secretion during immunogenic cell death
Martins, I., Wang, Y., Michaud, M., Ma, Y., Sukkurwala, A. Q., Shen, S., Kepp, O., Métivier, D., Galluzzi, L., Perfettini, J.-L., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.75 · Cited by 563 · cited 3×
“…containing protein kinase 1 (ROCK1)-dependent fusion of exocytosis-competent ATP-rich vesicles with the plasma membrane (Imura et al , 2013; Martins et al , 2014); (ii) liberation of cytosolic ATP molecules via gap junction protein alpha 1 (GJA1, best known as CX43) hemichannels at gap…”
InfluentialSelf-citationCaloric restriction mimetics enhance anticancer immunosurveillance
Pietrocola, F., Pol, J., Vacchelli, E., Rao, S., Enot, D. P., Baracco, E. E., Levesque, S., Castoldi, F., Jacquelot, N., Yamazaki, T., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.016 · Cited by 542 · cited 3×
“…models of fibrosarcoma, correlating with decreased infiltration by T REG cells, via a mechanism that depends on expression of the essential autophagy gene autophagy-related 5 ( ATG5 ) in cancer cells and intact immune responses (Pietrocola et al , 2016; Castoldi et al , 2020; Wu et al , 2020b).”
Metabolic landscape of the tumor microenvironment at single cell resolution
Xiao, Z., Dai, Z., & Locasale, J. W. (2019) · Nature Communications · doi:10.1038/s41467-019-11738-0 · Cited by 524 · cited 1×
“…as Darwinian pressures, fostering the selection of cells with an accrued capacity to harness alternative carbon sources ( e.g ., lactate, extra-cellular amino acids) for catabolic and anabolic reactions in support of proliferation and tolerance to hypoxia (Chang et al , 2015; Xiao et al , 2019).”
López-Otín, C., & Kroemer, G. (2021) · Cell · doi:10.1016/j.cell.2020.11.034 · Cited by 499
Self-citationImmunological impact of cell death signaling driven by radiation on the tumor microenvironment
Rodriguez-Ruiz, M. E., Vitale, I., Harrington, K. J., Melero, I., & Galluzzi, L. (2020) · Nature Immunology · doi:10.1038/s41590-019-0561-4 · Cited by 385
Self-citationCancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
Vesely, M. D., & Schreiber, R. D. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12105 · Cited by 367 · cited 2×
“…precursors, in some instances newly formed cancer cells can resist immune attacks and generate a rudimentary tumor microenvironment that enables some degree of proliferation, a dynamic battle between emerging tumors and their host commonly referred to as “equilibrium” (Vesely & Schreiber, 2013).”
Autophagy in the renewal, differentiation and homeostasis of immune cells
Clarke, A. J., & Simon, A. K. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-018-0095-2 · Cited by 361
Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy
Yamazaki, T., Kirchmair, A., Sato, A., Buqué, A., Rybstein, M., Petroni, G., Bloy, N., Finotello, F., Stafford, L., Navarro Manzano, E., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0751-0 · Cited by 359
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
Goswami, S., Walle, T., Cornish, A. E., Basu, S., Anandhan, S., Fernandez, I., Vence, L., Blando, J., Zhao, H., Yadav, S. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0694-x · Cited by 356 · cited 1×
“…signaling mediates anticancer effects per se (at least in various models), blocking additional immunosuppressive pathways such as those controlled by co-inhibitory receptors appears to provide improved disease control in most cases (Beavis et al , 2017; Leone et al , 2018; Goswami et al , 2020).”
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Fong, L., Hotson, A., Powderly, J. D., Sznol, M., Heist, R. S., Choueiri, T. K., George, S., Hughes, B. G. M., Hellmann, M. D., Shepard, D. R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0980 · Cited by 352
Li, J., Wang, L., Chen, X., Li, L., Li, Y., Ping, Y., Huang, L., Yue, D., Zhang, Z., Wang, F., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1320011 · Cited by 299
Sitkovsky, M. V., Hatfield, S., Abbott, R., Belikoff, B., Lukashev, D., & Ohta, A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0075 · Cited by 215
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
Buqué, A., Bloy, N., Perez-Lanzón, M., Iribarren, K., Humeau, J., Pol, J. G., Levesque, S., Mondragon, L., Yamazaki, T., Sato, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17644-0 · Cited by 138
Self-citationKjaergaard, J., Hatfield, S., Jones, G., Ohta, A., & Sitkovsky, M. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700850 · Cited by 132
Type I interferons and dendritic cells in cancer immunotherapy
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124 · cited 1×
“…I conventional dendritic cells (cDC1s), T H 1 CD4 + T cells, CD8 + cytotoxic T lymphocytes (CTLs), and natural killer (NK) cells, all of which promote tumor-targeting immunity (Talmadge & Gabrilovich, 2013; Mantovani et al , 2017; Lee & Radford, 2019; Sprooten et al , 2019; Togashi et al , 2019).”
Ladoire, S., Enot, D., Senovilla, L., Ghiringhelli, F., Poirier-Colame, V., Chaba, K., Semeraro, M., Chaix, M., Penault-Llorca, F., Arnould, L., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1154244 · Cited by 117
Self-citationAntihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy
Hatfield, S. M., & Sitkovsky, M. V. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137554 · Cited by 73
Cited by
Immunogenic cell stress and death
Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353
Self-citationMitochondrial control of inflammation
Marchi, S., Guilbaud, E., Tait, S. W. G., Yamazaki, T., & Galluzzi, L. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00760-x · Cited by 1,027
Self-citationDendritic cell subsets in cancer immunity and tumor antigen sensing
Del Prete, A., Salvi, V., Soriani, A., Laffranchi, M., Sozio, F., Bosisio, D., & Sozzani, S. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00990-6 · Cited by 644
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Self-citationTargeting immunogenic cell stress and death for cancer therapy
Galluzzi, L., Guilbaud, E., Schmidt, D., Kroemer, G., & Marincola, F. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00920-9 · Cited by 538
Self-citation
Metadata
- Authors
- Kepp, O., Bezu, L., Yamazaki, T., Di Virgilio, F., Smyth, M. J., Kroemer, G., & Galluzzi, L.
- Venue
- The EMBO Journal
- Published
- 2021-06-14
- Volume
- 40
- Issue
- 13
- Pages
- e108130-e108130
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- OpenAlex
- W3171454144
- Cited by
- 229
- References
- 30
- FWCI
- 20.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.